In conclusion, our study identified HSD3B7 as a novel prognostic biomarker and potential therapeutic target in ccRCC through an integrated analysis of single-cell and bulk RNA-seq data. Here, HSD3B7 is linked to nonpapillary renal cell carcinoma.